Trevor James
Ebola is a deadly and highly infectious disease that has caused several outbreaks and thousands of deaths. The development of a vaccine has been challenging due to the unpredictable nature of Ebola outbreaks and the rarity of the disease. However, there are currently two licensed Ebola vaccines: a single-dose Ad5-EBOV vaccine in China and a two-dose rVSV/Ad5 vaccine licensed in the Russian Federation for emergency use. The first vaccine to be approved in the US was rVSV-ZEBOV, also known as ERVEBO, in December 2019. This vaccine is also approved by the FDA and is maintained in the US Strategic National Stockpile. While these vaccines are a significant development in the fight against Ebola, they are not 100% effective, and it is important to continue following safety guidelines and infection control procedures.
| Characteristics | Values |
|---|---|
| Number of Ebola vaccines | 2 licensed vaccines and 2 investigational vaccines |
| Licensed vaccines | a single-dose Ad5-EBOV vaccine in China and a 2-dose rVSV/Ad5 vaccine licensed in the Russian Federation |
| Investigational vaccines | rVSV-ZEBOV vaccine made by Merck and the Ad26.ZEBOV/MVA-BN-Filo vaccine by Janssen |
| FDA-approved vaccine | ERVEBO® |
| FDA approval date | December 2019 |
| EU approval date | November 2019 |
| Vaccine regimen | Safe and could induce an immune response against the Ebola virus |
| Ring vaccination | A strategy to vaccinate individuals at highest risk of infection due to their connection to a patient confirmed with the virus |
| Vaccines not 100% effective | Yes |
| Vaccine side effects | Pain, swelling and redness at the injection site, headache, fever, muscle pain, tiredness and joint pain |
Explore related products
What You'll Learn
- The Ervebo vaccine is only effective against one of the viruses that cause Ebola
- Vaccinated individuals must continue to adhere to biosafety guidelines and infection prevention measures
- The World Health Organization recommends the use of Ervebo in pregnant and breastfeeding women in areas with an active Ebola outbreak
- The first vaccine to be approved in the US was rVSV-ZEBOV in December 2019
- The CDC Ebola Vaccine Program will respond to eligible requests with instructions and required forms
The Ervebo vaccine is only effective against one of the viruses that cause Ebola
The Ebola virus is a deadly and highly infectious disease that has caused several outbreaks and claimed thousands of lives. The World Health Organization (WHO) and other health authorities have been working to develop and deploy vaccines to prevent and control Ebola outbreaks. While there have been several vaccine candidates and clinical trials, as of 2022, there are only vaccines available against the Zaire ebolavirus.
One of the approved vaccines is Ervebo, which has been authorized for use in the United States, the European Union, and several African countries. Ervebo is a vaccine based on the vesicular stomatitis virus (VSV), which was genetically modified to express a surface glycoprotein of the Zaire Ebola virus. It is important to note that Ervebo is specifically effective against the Orthoebolavirus zairense, which is one of the viruses that cause Ebola disease.
The development and approval of the Ervebo vaccine is a significant milestone in the fight against Ebola. However, it is important to recognize that this vaccine is not a cure-all for all strains of the Ebola virus. The Ebola virus is caused by a group of viruses known as ebolaviruses, primarily found in sub-Saharan Africa. While Ervebo offers protection against one of these viruses, it is not effective against all the other species of ebolaviruses that can cause the disease.
The effectiveness of the Ervebo vaccine in providing protection against a specific strain of the Ebola virus is a testament to the power of scientific research and collaboration. The development process involved various organizations, including the Public Health Agency of Canada and Merck Inc. The vaccine underwent rigorous clinical trials and was found to be safe and effective in preventing Ebola disease caused by the Orthoebolavirus zairense species.
Despite the success of the Ervebo vaccine, ongoing research and development are crucial to address the diverse strains of the Ebola virus. The unpredictable nature of Ebola outbreaks and the constant evolution of the virus require a comprehensive approach. This includes exploring different vaccination strategies, such as routine vaccinations in high-risk regions, pre-exposure vaccinations for frontline workers, and emergency vaccinations in outbreak zones.
Hepatitis B & C: Vaccines and Their Availability
You may want to see also
Explore related products
Vaccinated individuals must continue to adhere to biosafety guidelines and infection prevention measures
There are currently two licensed Ebola vaccines: a single-dose Ad5-EBOV vaccine in China and a 2-dose rVSV/Ad5 vaccine licensed in the Russian Federation for "emergency use". There are also two investigational vaccines, the rVSV-ZEBOV vaccine made by Merck and the Ad26.ZEBOV/MVA-BN-Filo vaccine by Janssen. The first vaccine to be approved in the US was rVSV-ZEBOV in December 2019. It is sold under the brand name Ervebo and is the only FDA-approved vaccine to prevent Ebola disease.
While these vaccines are safe and effective, they are not 100% effective. Vaccinated individuals must continue to adhere to biosafety guidelines and infection prevention measures. This is especially important for laboratory staff and healthcare workers at risk of occupational exposure to the Ebola virus. They must wear recommended personal protective equipment and follow proper procedures to prevent infection.
Vaccinated individuals should avoid touching a patient's body (dead or alive) or bodily fluids, including blood, vomit, saliva, urine, or faeces. They should also avoid personal items used by the patient, such as bedding and clothes, as they may be contaminated with the virus. If a vaccinated individual was already infected with the Ebola virus before vaccination, they could still develop Ebola disease after receiving the vaccine. In such cases, they should immediately contact the vaccination team if they develop any symptoms of illness.
Pregnant and lactating women are generally not included in vaccine trials due to potential risks to the fetus and infant. However, during the 2018-2020 outbreak in the Democratic Republic of Congo, the Ervebo vaccine was used in pregnant and lactating women under a compassionate use protocol. The Strategic Advisory Group of Experts (SAGE) is reviewing the safety data for this population, and further recommendations are expected. While pregnancy and lactation are not absolute exclusion criteria for receiving Ervebo, live attenuated vaccines are generally contraindicated during pregnancy. Women of reproductive age should be counselled on the potential fetal risks of vaccination, and the decision to receive the vaccine should be made on an individual basis in consultation with a healthcare provider.
Influenza Vaccine Options for Seniors Over 65
You may want to see also
Explore related products
The World Health Organization recommends the use of Ervebo in pregnant and breastfeeding women in areas with an active Ebola outbreak
The Ebola virus is a highly infectious disease that has caused several deadly outbreaks in recent years. The World Health Organization (WHO) has recommended the use of the Ervebo vaccine in pregnant and breastfeeding women in areas with an active Ebola outbreak. This recommendation is based on several factors and is made in specific contexts.
Firstly, the Ervebo vaccine has been deemed safe and effective by the U.S. Food and Drug Administration (FDA) for the prevention of the Ebola virus disease. It is a live, attenuated recombinant vesicular stomatitis virus (VSV) vaccine. While the manufacturer's recommendation is that the vaccine is for adults over 18 years of age, excluding pregnant and lactating women, the Strategic Advisory Group of Experts (SAGE) on Immunization has recommended its use in these women under a compassionate use clinical protocol.
During the 2018-2020 outbreak in Ituri, North Kivu, and South Kivu in the Democratic Republic of the Congo, the vaccine was used in pregnant and lactating women. The SAGE is reviewing the safety data for this vulnerable population, and further recommendations are expected. It is important to note that while pregnancy and lactation are not absolute exclusion criteria for receiving Ervebo, live attenuated vaccines are generally contraindicated during pregnancy. Therefore, the potential risks and benefits should be carefully considered on an individual basis, in consultation with a healthcare provider.
The WHO's recommendation for this specific context—an active Ebola outbreak—is based on rigorous research and the potential benefit of protection against the deadly virus. The risk of exposure to Ebola must be weighed against the potential vaccine-related risks during pregnancy and breastfeeding. This decision-making process should consider the mother's clinical need for the vaccine, the child's development, and the health benefits of breastfeeding. Additionally, any potential adverse effects on the breastfed child, either from the vaccine or from the mother's risk of contracting Ebola, should be carefully evaluated.
The Ervebo vaccine is part of a ring vaccination strategy, targeting individuals at the highest risk of contracting Ebola during an outbreak. This strategy involves vaccinating close contacts of infected patients, including those who lived in the same household or were in close physical contact with the patient or their bodily fluids and belongings. Ring vaccination has been successfully employed in the past to eradicate smallpox.
The Race for an RSV Vaccine: Is It Possible?
You may want to see also
Explore related products
The first vaccine to be approved in the US was rVSV-ZEBOV in December 2019
The Ebola virus, a deadly and highly infectious disease, has had a vaccine approved for use in the US. The first vaccine to be approved in the US was rVSV-ZEBOV in December 2019. This vaccine was developed by the Public Health Agency of Canada and is based on the vesicular stomatitis virus, which was genetically modified to express a surface glycoprotein of the Zaire Ebola virus.
The rVSV-ZEBOV vaccine was used extensively in the Kivu Ebola epidemic under a compassionate use protocol. It was also used in a ring vaccination study in Guinea during the 2015 outbreak of EVD in West Africa, with high efficacy. This strategy involves vaccinating individuals at the highest risk of infection due to their connection to a patient with a confirmed case of the virus.
The vaccine was approved for use in the US by the Food and Drug Administration (FDA) and is the only FDA-approved vaccine to prevent Ebola disease. It is maintained in the US Strategic National Stockpile and is not planned for commercial marketing. The FDA's approval was based on the "animal efficacy rule", which allows licensure based on animal model studies that replicate human disease.
The rVSV-ZEBOV vaccine is also one of only two licensed Ebola vaccines, the other being a single-dose Ad5-EBOV vaccine in China. Several other vaccines are currently being investigated, including an Ad26.ZEBOV/MVA-BN-Filo vaccine.
Baby Got Fever Post-Vaccination? Here's What to Do
You may want to see also
Explore related products
The CDC Ebola Vaccine Program will respond to eligible requests with instructions and required forms
The Ebola virus disease is a rare disease that most commonly affects people and non-human primates, such as monkeys, gorillas, and chimpanzees. The disease spreads through direct contact with the blood, bodily fluids, and tissues of infected people or animals, or those who have died from the disease. Healthcare workers, laboratory staff, and family and friends in close contact with infected individuals are at the highest risk of contracting the disease.
The CDC Ebola Vaccine Program aims to ensure the availability of Ebola vaccine doses for emergency outbreak response. The program established an Ebola vaccine stockpile in 2021 to provide equitable and rapid access to vaccines during an outbreak. The program will respond to eligible requests with instructions and required forms, detailing the specific criteria that must be met for individuals to receive the vaccine.
The Ervebo vaccine, manufactured by Merck, is a safe and effective vaccine approved by the U.S. Food and Drug Administration (FDA) to prevent Ebola disease. It is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (VSV) vaccine. The vaccine contains only a gene from the Ebola virus, not the whole virus, so it cannot cause an Ebola infection. Clinical studies have shown that the vaccine is effective in preventing Ebola disease, with no reported cases among vaccinated individuals 10 or more days after vaccination.
However, it is important to note that the Ervebo vaccine is only effective against one of the viruses that cause Ebola disease. The vaccine is indicated for individuals 12 months of age and older, excluding pregnant and lactating women, although there have been exceptions during outbreaks. Healthcare providers must consider contraindications, precautions, and specific population considerations before administering the vaccine. For example, individuals with a history of severe allergic reactions to rice protein should not receive the vaccine due to its rice-derived recombinant human serum albumin content.
The CDC provides resources such as the Ebola Vaccine Information Statement (VIS) and the Countermeasures Injury Compensation Program to support individuals seeking information about the Ebola vaccine. The program assists individuals who have suffered serious injuries from certain medicines or vaccines with medical care costs and other specific expenses.
Hepatitis C Vaccine: What's the Best Description?
You may want to see also
Frequently asked questions
Yes, there are currently two licensed Ebola vaccines: a single-dose Ad5-EBOV vaccine in China and a 2-dose rVSV/Ad5 vaccine licensed in the Russian Federation for "emergency use".
The Ervebo vaccine is indicated for use for adults over 18 years of age, not including pregnant and lactating women. However, during the 2018-2020 outbreak in Ituri, North Kivu, and South Kivu in the Democratic Republic of the Congo, the vaccine was used in children over 6 months old and in pregnant and lactating women.
No vaccine is 100% effective. Vaccinated individuals should continue to protect themselves from the Ebola virus by avoiding contact with bodily fluids, personal items, and the patient's body, whether dead or alive.
